Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 3293 2022-11-30 14:24:38 |
2 format correct Meta information modification 3293 2022-12-01 02:06:17 | |
3 format correct + 3 word(s) 3296 2022-12-01 02:07:23 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Li, X.;  Wu, Y.;  Tian, T. Mechanism of TGF-β Functions in mCRC. Encyclopedia. Available online: https://encyclopedia.pub/entry/37361 (accessed on 23 April 2024).
Li X,  Wu Y,  Tian T. Mechanism of TGF-β Functions in mCRC. Encyclopedia. Available at: https://encyclopedia.pub/entry/37361. Accessed April 23, 2024.
Li, Xiaoshuang, Yanmin Wu, Tian Tian. "Mechanism of TGF-β Functions in mCRC" Encyclopedia, https://encyclopedia.pub/entry/37361 (accessed April 23, 2024).
Li, X.,  Wu, Y., & Tian, T. (2022, November 30). Mechanism of TGF-β Functions in mCRC. In Encyclopedia. https://encyclopedia.pub/entry/37361
Li, Xiaoshuang, et al. "Mechanism of TGF-β Functions in mCRC." Encyclopedia. Web. 30 November, 2022.
Mechanism of TGF-β Functions in mCRC
Edit

Colorectal cancer (CRC) is a serious public health issue, and it has the leading incidence and mortality among malignant tumors worldwide. CRC patients with metastasis in the liver, lung or other distant sites always have poor prognosis. CRC metastasis is a dynamic, multistep and multifactorial process, which includes the following successive steps: detachment from the primary CRC site, infiltration into adjacent tissues, invasion into blood/lymphatic circulation, transportation through the circulatory system, intravasation from vasculature and formation of CRC colonies in distant sites. Three critical factors contribute to CRC cells migration (pivotal for early metastasis): regulating the epithelial–mesenchymal transition (EMT) process, stemness and the microenvironment of CRC cells. Additionally, angiogenesis facilitates CRC cell transportation to distal locations. TGF-β signaling contributes to mCRC mainly through the following four mechanisms: promoting EMT, facilitating angiogenesis, creating an immunosuppressive microenvironment and regulating the stemness of mCRC .

colorectal cancer metastasis TGF-β signaling targeting therapy

1. TGF-β Signaling in EMT in mCRC

Epithelial cells undergoing EMT will lose their apicobasal polarity and adhesion, acquire motile mesenchymal characteristics and become more invasive, which contributes to the onset of CRC metastasis [1]. Epithelial and mesenchymal cells can be distinguished by specific molecular markers expressed in cells. For instance, epithelial cells express E-cadherin and cytokeratins, while N-cadherin, Snail, Slug and Vimentin are markers of mesenchymal cells [2]. Cells undergoing the EMT process are distinguished by the loss of E-cadherin expression, a decrease of epithelial cell junctions and cytoskeleton and display a mesenchymal pattern with enhanced cell motility and invasiveness [3].
TGF-β signaling is an essential regulator of the process of EMT. As reported, TGF-β can induce the EMT process by downregulating the expression of tight junction proteins, resulting in weakened tight junctions, which is the key point for EMT induction of TGF-β signaling [4]. SMAD4 is demonstrated to downregulate the expression of Claudin 1, which contributes to CRC metastasis [5]. Most of these observations were made in vitro, although the results of in vivo experiments are more convincing and important. In light of research in human SW480 CRC cells, TGF-β1 can induce Alu RNA expression, the accumulation of which promotes the EMT process, and Alu expression significantly correlates with CRC progression [6]. TGF-β1 upregulates the expression of C-terminal tensin-like (Cten) and EMT markers, and it promotes the cell motility of the CRC cell lines SW620 and HCT116 [7]. TGF-β1 can also induce the upregulation of acyl-CoA synthetases 3 (ACSL3) which produces ATP and reduces NADPH, thus sustaining redox homeostasis and mediating the EMT and metastasis of CRC cells [8]. A functional study indicated that TGF-β can induce SMAD4-dependent EMT followed by apoptosis in HCT-116 and DLD1 CRC cell lines [9]. As reported in CRC cell assays and murine models, acidosis-induced TGF-β2 activation promotes the formation of lipid droplets, which provides energy for cancer cell metastasis and partially promotes EMT [10]. SMAD4 in TGF-β signaling is frequently inactivated in human CRC, and SMAD4 codes for a transcription factor central to canonical TGF-β signaling. Therefore, it is generally understood that EMT will not occur in SMAD4-mutant tumors. However, in SMAD4-mutant CRC cell lines and analyses of human CRC transcriptomes, EMT is not categorically precluded. Possible explanations for this may be that SMAD4-mutant tumors escape the tumor-suppressive function of TGF-β or undergo SMAD4-independent EMT [11]. Moreover, CRC patient tissues exhibited higher GDF-15 expression compared with non-cancerous controls, and in the human CRC cell line LoVo, the overexpression of GDF-15 could upregulate the marker genes of mesenchymal cells. Thus, GDF-15 could lead to EMT and promote CRC cell invasion and migration [12]. Based on the systematic analysis of samples from seven CRC patients, it was found that some potential EMT biomarkers were enriched in TGF-β/Snail and TNF-α/nuclear factor-κB (NF-κB) pathways, and the integrated pathway may be the main axis connecting cancer cells with their TME during EMT [13]. In an immunohistochemical study of 48 resected CRC specimens, SMAD4 was positively linked with the expression of Snail-1, Slug and Twist-1, while it was negatively correlated with E-cadherin expression, implying that SMAD4 promotes the process of EMT [14].
There are also other factors that affect EMT by regulating the TGF-β pathway. For example, atypical protein kinase C-ι (aPKC-ι) knockdown inhibits TGF-β1-induced EMT and cell migration in CRC cells [15]. Furthermore, in 5-fluorouracil (5-FU)-resistant CRC cell lines, knockdown of transmembrane protein 45A (TMEM45A) attenuated multidrug-resistance-enhanced EMT by suppressing the TGF-β/SMAD signaling pathway [16]. In studies utilizing cell line experiments and nude mouse models, Numb expression was negatively correlated with TNM stage and lymph node metastasis, and inhibiting Numb expression promoted the EMT process and the invasion of CRC cells induced by TGF-β [17]. It was found that Paraneoplastic antigen Ma family number 5 (PNMA5) accelerated CRC cell proliferation, invasion and migration in nude mice lung metastasis models, and the knockdown of PNMA5 attenuated TGF-β-induced EMT in CRC cells [18]. As reported in cell assays and mouse xenograft tumors, beta human chorionic gonadotropin (hCGβ) changed expression of EMT-associated genes, and these changes could be reversed by TGFBR1 and TGFBR2 inhibitors, indicating that hCGβ induces EMT in a manner that depends on the TGF-β pathway [19].

2. TGF-β Signaling in Angiogenesis in mCRC

Angiogenesis in the TME is a pivotal process that promotes tumor development and metastasis [20]. Newly formed blood vessels can provide oxygen and nutrients to tumor cells as well as allow them to enter into blood circulation and metastasize to distant sites [21].
First, the TGF-β pathway can regulate tumor metastasis by affecting vascular endothelial growth factor (VEGF). In the CRC HCT116 cell line, the upregulation of VEGF expression caused by the absence of SMAD4 enhanced vascular density and promoted the development of metastasis [22]. Additionally, SMAD4 overexpression can inhibit CRC growth by inhibiting VEGF-A and VEGF-C expression in the HCT116 cell line and an promote tumor cell apoptosis in HCT116 cells and nude mouse models [23]. There are primarily two histopathological patterns of vascular changes in CRLM: angiogenic desmoplastic and non-angiogenic replacement [24]. Overexpression of Runt-Related Transcription Factor-1 (RUNX1) in cancer cells of the replacement lesions, which is mediated by TGF-β1 and thrombospondin 1 (TSP1), enhances cell motility to achieve vessel co-option [24]. TGF-β expression is increased in the AlCl3-exposed human CRC cell line HT-29, and this particularly promoted endothelial cell angiogenesis via the induction of VEGF secretion [25]. In an orthotopic mouse model of liver metastasis, the inhibition of TGF-β-induced protein ig-h3 (TGFBI) suppressed angiogenesis of CRC cells and inhibited the progression of CRLM [26]. Second, the synergistic effects of TGF-β and other signal cascades can stimulate angiogenesis by accelerating endothelial cell migration and proliferation [3]. TGF-β can interact with other proteins or pathways to foster angiogenesis in mCRC. The downregulation of platelet-derived growth factor-D (PDGF-D), a downstream signal of TGF-β, inhibited the growth, migration and angiogenesis of CRC cells in vitro and in vivo [27]. Thrombospondin-4 (THBS4), an ECM protein, plays an essential role in the TME and augments the effects of TGF-β1 on angiogenesis [28][29].

3. TGF-β Signaling in Immunosuppressive Microenvironment in mCRC

Growing evidence has shown that the TME performs a significant role in tumor initiation, progression and metastasis. The TME comprises non-cancerous cells in the tumor, including cancer-associated fibroblasts (CAFs), endothelial cells, pericytes and different types of immune cells (dendritic cells (DCs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), natural killer (NK) cells, myeloid cells, T cells, B cells, monocytes etc.), as well as non-cellular components, including ECM and soluble products such as collagen, various cytokines, chemokines and other factors that contribute to CRC metastasis [30][31][32]. Direct cell-to-cell contact between cancer cells and secretion of cytokines in the TME caused crosstalk, resulting in CRC progression and ultimately metastasis. It was reported that the activity of TGF-β signaling in TME cells such as T cells, macrophages, endothelial cells and fibroblasts improved the organ colonization efficiency of CRC cells, while treating the mice with the TGFBR1-spesific inhibitor LY2157299 inhibited CRC metastasis formation [33]. Elevated TGF-β expression levels is an important feature in the TME of CRC, and TGF-β signaling can regulate the development of CRC, form the system structure of tumors and inhibit the activity of anti-tumor immune cells, which results in an immunosuppressive microenvironment [34][35][36].
Here it summarize recent research and find that most of studies focused on CAFs and immune cells such as TAMs, TANs, DCs, T cells, myeloid cells and monocytes. Only a few studies on TGF-β signaling-mediated CRC progression and metastasis were related to collagen (discussed in the CAF section). TGF-β-signaling-related CRC metastasis involving CAFs and immune cells will be further discussed in detail in the following sections.

3.1. CAFs

CAFs are the most numerous cells in the TME, and they affect CRC metastasis by regulating TGF-β signaling directly or indirectly [36][37]. TGF-β is mainly produced by CAFs in CRC, and increased TGF-β promotes T cell exclusion and inhibits the effector phenotype acquisition of type 1 T helper cells (TH1). It has been reported that inhibition of TGF-β enhances the cytotoxic T cell response to tumor cells, thus suppressing liver metastasis [38]. TGF-β activates CAFs to secrete activin A, a TGF-β family member, which induces colon epithelial cell migration and EMT, resulting in a more metastatic phenotype of CRC [39]. Wang et al. have recently reported that the activation of C-X-C motif chemokine ligand 12 (CXCL12)/CXCR7 axis drove CRC cells to secrete exosomal miR-146a-5p and miR-155-5p, which could be taken up by CAFs, thus enhancing CAF activation via JAK2-STAT3/NF-κB signaling. CAFs could secrete more inflammatory cytokines, including TGF-β, further promoting EMT and CRC metastasis to the lung in vivo [40]. ZNF37A, which is upregulated in CRC, is reported to facilitate tumor cell metastasis to the lung and liver via the activation of Thrombospondin Type-1 Domain-Containing protein 4 (THSD4)/TGF-β signaling, and increased TGF-β secretion contributes to transforming fibroblasts to CAFs in the TME, further promoting CRC metastasis [41]. Integrin αvβ6 secreted by CRC cells induced the expression of TGF-β, thereby converting fibroblasts into CAFs and promoting CRC metastasis through the stromal cell derived factor-1 (SDF-1)/C-X-C motif chemokine receptor type 4 (CXCR4) axis [42]. Treatment of co-cultured CRC and CAF-like cells with vincristine, which is a chemotherapy drug used widely in mCRC clinical treatment, increased the secretion of TGF-βs, induced EMT and promoted the formation of CAFs, thereby enhancing the invasion and metastasis of CRC [43]. Interleukin-11 (IL-11) secreted by TGF-β-stimulated CAFs is a TGF-β target gene, and it activated GP130/signal transducer and activator of transcription 3 (STAT3) signaling in CRC cells and promoted the initiation of CRC cells to metastasis [33]. Endoglin, a TGF-β family coreceptor produced by CAFs, enhanced CRC cell metastasis to the liver in both zebrafish and mouse models [44]. In addition, it has been demonstrated that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) secreted by SMAD4-deficient CRC cells promotes fibroblasts to produce BMP2, resulting in CRC cell invasion and metastasis [45].
Moreover, TGF-β1 can be secreted by tumor cells in metastasis. Neutral endopeptidase (NEP) co-culturing human colon cancer cell line SW620 (derived from metastatic tumors) with normal colon fibroblasts induced a significant increase in expression of TGF-β1 in SW620 cells, and this effect could be reversed by deletion of NEP [46]. As reported, TGF-β1 promoted the co-migration of colon cancer cells and CAFs, resulting in enhanced liver metastasis and tumor burden [47]. CAF-derived exosomal microRNA (miR)-17-5p caused CRC cells to secrete TGF-β1 into the TME through RUNX3/MYC/TGF-β1 signaling, which triggered CAFs to release more exosomal miR-17-5p to CRC cells, thus establishing a positive feedback loop for CRC metastasis [48]. In CRC, fibroblasts could be converted to CAFs via IL-1β/TGF-β1 signaling, and both TGF-β-activated kinase 1 (TAK1) and TGFBR1 inhibitors suppressed CRC metastasis and CAF accumulation [49]. Two additional studies revealed that CXCR4/TGF-β1 signaling plays an important role in the transformation of mesenchymal stem cells or hepatic stellate cells into CAFs, further promoting CRLM [50][51].
However, CAFs can also suppress CRC progression in some situations. In a genetically modified metastatic CRC mouse model, depletion of alpha smooth muscle actin (αSMA)+ CAFs resulted in an increase of forkhead box protein 3 (Foxp3)+ regulatory T cells (Tregs) and suppression of CD8+ T cells via BMP4/TGF-β1 paracrine signaling, ultimately promoting CRC invasiveness and lymph node metastasis [52]. A recent study showed that gremlin 1 (GREM1) and the immunoglobulin superfamily contain leucine-rich repeat (ISLR), representing two different types of fibroblast subpopulations that exert opposing roles in the signal transduction of BMP. Neutralization of GREM1 or overexpression of ISLR in fibroblasts could reduce CRC hepatic metastasis [53].
Furthermore, decreased expression of hyaluronan and proteoglycan link protein-1 (HAPLN1) regulated collagen deposition in CRC via the TGF-β signaling pathway, and increased collagen resulted in TME changes and CRC cell proliferation, migration and invasion [54].

3.2. Immune Cells

TAMs, one of the most common immune cells in the TME, have been reported as key contributors to promote tumor metastasis [55][56]. Liu et al. found severe TAM infiltration in tumor tissues of mCRC patients, and TAM-derived TGF-β could activate HIF1α/TRIB3/β-catenin/Wnt signaling to enhance CRC progression [57]. GDF-15, secreted by macrophages, is a divergent member of the human TGF-β superfamily, and it can increase expression of EMT genes, thereby promoting the invasion and metastasis of CRC via the ERK1/2/c-Fos signaling pathway [58]. Shimizu et al. found that Kupffer cells, known to be resident hepatic macrophages, released TGF-β1 and promoted liver metastasis of CRC through angiotensin II subtype receptor 1a (AT1a) signaling. Moreover, depletion of Kupffer cells reduced metastatic areas [59]. It has been proven that TGF-β1 secretion of CRC cells upregulated macrophage expression of Response Gene to Complement 32 (RGC-32) and thus enhanced macrophage migration and promoted tumor progression [60]. Recently, Chen et al. found that oxaliplatin-based chemotherapy induced TAM recruitment to release TGF-β, which was mediated by CRC-cell-derived CSF1, resulting in programmed cell death-Ligand 1 (PD-L1) upregulation and an immunosuppressive TME. Inhibition of PD-L1 expression in CRC could make cancer cells sensitive to chemotherapy, reduce CRC lung metastasis and increase infiltration of CD8+ T cells. Both CSF1R+ TAM depletion and TGF-β receptor blockade combined with chemotherapy could inhibit tumor growth significantly [61]. Through specific differentiation, macrophages can be polarized into two different phenotypes: activated M1-type and alternatively activated M2-type. M1-type macrophages inhibit tumor growth and progression, whereas M2-type macrophages induce the progression and metastasis of tumors in CRC [55][62]. Ma et al. found that M2-type macrophages were positively correlated with infiltrating Foxp3+ Tregs in CRC, which may promote the development of CRC via the TGF-β/SMAD signaling pathway [63]. Cai et al. reported that M2-type macrophages that secreted TGF-β promoted EMT by activating the SMAD2,3-4/Snail/E-cadherin signaling pathway, resulting in CRC lung metastasis [64]. Zhang et al. revealed that Collagen Triple Helix Repeat Containing 1 (CTHRC1) secreted by CRC cells induced macrophages to the M2-type through activation of TGF-β signaling, further enhancing CRC liver metastasis [65]. Recently, Li et al. developed a thermosensitive hydrogel called Gel/(regorafenib + NG/LY3200882 (LY)), which could sequentially release regorafenib and LY (a selective TGF-β inhibitor) in tumor cells. Using colorectal tumor-bearing mouse models, they found that Gel/(regorafenib + NG/LY) can effectively inhibit tumor growth and liver metastasis, which was achieved by increasing levels of CD8+ T cells, reducing infiltration of TAMs and myeloid-derived suppressor cells and shifting macrophage polarization from M2-type to M1-type in TME [66].
Apart from CAFs and TAMs, other cellular components, such as TANs, myeloid cells, monocytes, DCs and T cells, in the TME can also affect CRC metastasis through TGF-β signaling. TAN infiltration was demonstrated to be positively correlated with the clinical stage of CRC patients [67]. Anti-TGF-β treatment attenuated tumor growth, which was mediated by inhibition of PI3K/AKT signaling pathways in TANs and TGF-β/SMAD signaling pathways in CRC cells [68]. Activation of epithelial NOTCH1 enhanced epithelial TGF-β2 expression and facilitated liver metastasis of CRC through TAN infiltration, which was mediated by TGF-β signaling. Neutrophil depletion led to increased CD8+ T cells in both primary tumors and livers and decreased metastasis. In addition, blocking TGF-β signaling in neutrophils can effectively reduce CRC metastasis [69]. Using mouse xenograft models, Itatani et al. found that a deficiency of SMAD4 in human CRC cells upregulated CCL15 expression, thus recruiting CCR1+ myeloid cells and promoting liver metastasis of CRC [70]. Furthermore, inflammation is an important driver for CRC development and metastasis. CRC cells treated with lipopolysaccharide-stimulated monocyte conditioned medium showed reduced expression of Growth Factor Independence 1 and enhanced EMT and CRC cell metastatic formation, which might have been mediated by TGF-β signaling [71]. Wang et al. suggested that silencing poly (ADP-ribose) glycohydrolase (PARG) in CT26 cells could suppress liver metastasis of colon carcinoma by suppression of poly (ADP-ribose) polymerase (PARP) and NF-κB and that it could reduce secretion of IL-10 and TGF-β, thus promoting the proliferation and differentiation of DCs and T cells, resulting in inhibition of metastasis by changes in immune function [72]. Treg and T helper 17 (Th17)-related genes seem to contribute greatly to CRC development and progression. Miteva et al. investigated the expression of Treg and Th17-related genes in CRC tissues and found that Foxp3, IL-10 and TGF-β1 expression was increased in CRC metastases in contrast to IL17A and NOS2. Treg and Th17-related gene expression in both primary tumor and regional lymph nodes might provide a suitable microenvironment for accelerating CRC metastasis [73]. The mechanism by which other cells in the TME influence T cells via TGF-β signaling directly or indirectly was covered in the previous section [38][52][61][63][66][69][72].

4. TGF-β Signaling in Stemness in mCRC

Most tumors, including CRC, contain a small population of cancer stem cells (CSCs) which are regarded as key contributors to tumor generation, progression, recurrence, metastasis and chemotherapy drug resistance [74][75]. According to recent studies, the TGF-β signaling pathway can affect metastasis of CRC by affecting CSCs in CRC or the stemness of CRC cells.
Mesenchymal stem cells co-cultured with CRC cells showed enhanced invasive ability, which was mediated by increased expression of TGF-β1 and decreased expression of p53, resulting in effective inhibition of CRC metastasis [76]. Reports suggested that TGF-β could convert Nur77’s role from cancer inhibition to cancer promotion, which is associated with CRC stemness, metastasis and oxaliplatin resistance [77]. CSCs have specific markers on their surface. CD51, a novel functional marker for colorectal CSCs, could increase the sphere-forming abilities, tumorigenic capacities and migratory potentials of CRC cells, and it may regulate EMT and chemoresistance through TGF-β/SMAD signaling [78]. In a novel mouse model of CRLM, proteomic analysis revealed that the expression of CRC stem cell markers in CRC cells was elevated compared with the non-metastatic model, and the expression of these markers was regulated negatively by the TGF-β/SMAD4 pathways [79].

5. Other Mechanisms of TGF-β in mCRC

In addition to the four mechanisms mentioned above, TGF-β can also affect the metastasis of CRC through some additional mechanisms. TGF-β regulates matrix metalloproteinase (MMP) expression in cancer cells, while MMPs produced by either cancer cells or stroma cells activate latent TGF-β, together facilitating progression of CRC [80]. The expression of TGF-β and the podocalyxin-like (PODXL) protein in CRC cells could increase under radiation and then promote ECM deposition, resulting in cell migration and invasiveness [81]. Bioinformatic analysis and functional characterization indicated that TGF-β and Snail promoted CRC migration by preventing degradation of the non-coding RNA LOC113230-related argininosuccinate synthase 1 (ASS1) [82]. Reports indicate that cancer epithelial cells show a robust outward apical pole throughout the process of dissemination, which is referred to as tumor spheres with inverted polarity (TSIPs). TSIPs form and propagate via the collective apical budding of hypermethylated CRCs downstream of TGF-β signaling, which could drive the formation of peritoneal metastases [83]. Moreover, TrkC, which was overexpressed in CRC, could also increase the ability to form tumor spheroids, thus enhancing the metastatic potential of CRC by activation of AKT and suppression of TGF-β signaling [84]. It has been demonstrated that TGF-β inhibits lymph angiogenesis by inhibiting collagen and calcium-binding EGF domain-1 (CCBE1) expression, and CCBE1 has a pro-tumorigenic role in lymphatic metastasis of CRC [85]. TGF-β2 could enhance the metastatic potential of human CRC cell lines via upregulating the expression of catalase and controlling H2O2 output [86].

References

  1. Vu, T.; Datta, P.K. Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers 2017, 9, 171.
  2. Lee, J.M.; Dedhar, S.; Kalluri, R.; Thompson, E.W. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J. Cell Biol. 2006, 172, 973–981.
  3. Seoane, J.; Gomis, R.R. TGF-beta Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harb. Perspect. Biol. 2017, 9, a022277.
  4. Tossetta, G.; Paolinelli, F.; Avellini, C.; Salvolini, E.; Ciarmela, P.; Lorenzi, T.; Emanuelli, M.; Toti, P.; Giuliante, R.; Gesuita, R.; et al. IL-1beta and TGF-beta weaken the placental barrier through destruction of tight junctions: An in vivo and in vitro study. Placenta 2014, 35, 509–516.
  5. Shiou, S.R.; Singh, A.B.; Moorthy, K.; Datta, P.K.; Washington, M.K.; Beauchamp, R.D.; Dhawan, P. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res. 2007, 67, 1571–1579.
  6. Di Ruocco, F.; Basso, V.; Rivoire, M.; Mehlen, P.; Ambati, J.; De Falco, S.; Tarallo, V. Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. Oncogene 2018, 37, 627–637.
  7. Asiri, A.; Raposo, T.P.; Alfahed, A.; Ilyas, M. TGFbeta1-induced cell motility but not cell proliferation is mediated through Cten in colorectal cancer. Int. J. Exp. Pathol. 2018, 99, 323–330.
  8. Quan, J.; Cheng, C.; Tan, Y.; Jiang, N.; Liao, C.; Liao, W.; Cao, Y.; Luo, X. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFbeta1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int. J. Biol. Sci. 2022, 18, 2484–2496.
  9. Siraj, A.K.; Pratheeshkumar, P.; Divya, S.P.; Parvathareddy, S.K.; Bu, R.; Masoodi, T.; Kong, Y.; Thangavel, S.; Al-Sanea, N.; Ashari, L.H.; et al. TGFbeta-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC. Mol. Cancer Ther. 2019, 18, 1312–1322.
  10. Corbet, C.; Bastien, E.; Santiago de Jesus, J.P.; Dierge, E.; Martherus, R.; Vander Linden, C.; Doix, B.; Degavre, C.; Guilbaud, C.; Petit, L.; et al. TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat. Commun. 2020, 11, 454.
  11. Frey, P.; Devisme, A.; Rose, K.; Schrempp, M.; Freihen, V.; Andrieux, G.; Boerries, M.; Hecht, A. SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer. Oncogene 2022, 41, 824–837.
  12. Zhang, Y.; Wang, X.; Zhang, M.; Zhang, Z.; Jiang, L.; Li, L. GDF15 promotes epithelial-to-mesenchymal transition in colorectal . Artif. Cell. Nanomed. Biotechnol. 2018, 46 (Suppl. 2), 652–658.
  13. Li, H.; Zhong, A.; Li, S.; Meng, X.; Wang, X.; Xu, F.; Lai, M. The integrated pathway of TGFbeta/Snail with TNFalpha/NFkappaB may facilitate the tumor-stroma interaction in the EMT process and colorectal cancer prognosis. Sci. Rep. 2017, 7, 4915.
  14. Ioannou, M.; Kouvaras, E.; Papamichali, R.; Samara, M.; Chiotoglou, I.; Koukoulis, G. Smad4 and epithelial-mesenchymal transition proteins in colorectal carcinoma: An immunohistochemical study. J. Mol. Histol. 2018, 49, 235–244.
  15. Du, G.S.; Qiu, Y.; Wang, W.S.; Peng, K.; Zhang, Z.C.; Li, X.S.; Xiao, W.D.; Yang, H. Knockdown on aPKC-iota inhibits epithelial-mesenchymal transition, migration and invasion of colorectal cancer cells through Rac1-JNK pathway. Exp. Mol. Pathol. 2019, 107, 57–67.
  16. Zhu, M.; Jiang, B.; Yan, D.; Wang, X.; Ge, H.; Sun, Y. Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-beta signalling pathway. Clin. Exp. Pharmacol. Physiol. 2020, 47, 503–516.
  17. Yang, Y.; Li, L.; He, H.; Shi, M.; He, L.; Liang, S.; Qi, J.; Chen, W. Numb inhibits migration and promotes proliferation of colon cancer cells via RhoA/ROCK signaling pathway repression. Exp. Cell Res. 2022, 411, 113004.
  18. Lin, J.; Zhang, X.; Meng, F.; Zeng, F.; Liu, W.; He, X. PNMA5 accelerated cellular proliferation, invasion and migration in colorectal cancer. Am. J. Transl. Res. 2022, 14, 2231–2243.
  19. Kawamata, F.; Nishihara, H.; Homma, S.; Kato, Y.; Tsuda, M.; Konishi, Y.; Wang, L.; Kohsaka, S.; Liu, C.; Yoshida, T.; et al. Chorionic Gonadotropin-beta Modulates Epithelial-Mesenchymal Transition in Colorectal Carcinoma Metastasis. Am. J. Pathol. 2018, 188, 204–215.
  20. Lee, H.-J. Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy. J. Cancer Prev. 2020, 25, 213–222.
  21. Akhurst, R.J.; Derynck, R. TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001, 11, S44–S51.
  22. Papageorgis, P.; Cheng, K.; Ozturk, S.; Gong, Y.; Lambert, A.W.; Abdolmaleky, H.M.; Zhou, J.R.; Thiagalingam, S. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011, 71, 998–1008.
  23. Li, X.; Li, X.; Lv, X.; Xiao, J.; Liu, B.; Zhang, Y. Smad4 Inhibits VEGF-A and VEGF-C Expressions via Enhancing Smad3 Phosphorylation in Colon Cancer. Anat. Rec. 2017, 300, 1560–1569.
  24. Rada, M.; Kapelanski-Lamoureux, A.; Petrillo, S.; Tabaries, S.; Siegel, P.; Reynolds, A.R.; Lazaris, A.; Metrakos, P. Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. Commun. Biol. 2021, 4, 950.
  25. Jeong, C.H.; Kwon, H.C.; Cheng, W.N.; Kim, D.H.; Choi, Y.; Han, S.G. Aluminum exposure promotes the metastatic proclivity of human colorectal cancer cells through matrix metalloproteinases and the TGF-beta/Smad signaling pathway. Food Chem. Toxicol. 2020, 141, 111402.
  26. Chiavarina, B.; Costanza, B.; Ronca, R.; Blomme, A.; Rezzola, S.; Chiodelli, P.; Giguelay, A.; Belthier, G.; Doumont, G.; Van Simaeys, G.; et al. Metastatic colorectal cancer cells maintain the TGFbeta program and use TGFBI to fuel angiogenesis. Theranostics 2021, 11, 1626–1640.
  27. Chen, J.; Yuan, W.; Wu, L.; Tang, Q.; Xia, Q.; Ji, J.; Liu, Z.; Ma, Z.; Zhou, Z.; Cheng, Y.; et al. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway. Oncotarget 2017, 8, 9961–9973.
  28. Muppala, S.; Frolova, E.; Xiao, R.; Krukovets, I.; Yoon, S.; Hoppe, G.; Vasanji, A.; Plow, E.; Stenina-Adognravi, O. Proangiogenic Properties of Thrombospondin-4. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 1975–1986.
  29. Muppala, S.; Xiao, R.; Krukovets, I.; Verbovetsky, D.; Yendamuri, R.; Habib, N.; Raman, P.; Plow, E.; Stenina-Adognravi, O. Thrombospondin-4 mediates TGF-beta-induced angiogenesis. Oncogene 2017, 36, 5189–5198.
  30. Derynck, R.; Turley, S.J.; Akhurst, R.J. TGFβ biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 2021, 18, 9–34.
  31. Tommelein, J.; Verset, L.; Boterberg, T.; Demetter, P.; Bracke, M.; De Wever, O. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front. Oncol. 2015, 5, 63.
  32. Hinshaw, D.C.; Shevde, L.A. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019, 79, 4557–4566.
  33. Calon, A.; Espinet, E.; Palomo-Ponce, S.; Tauriello, D.V.; Iglesias, M.; Cespedes, M.V.; Sevillano, M.; Nadal, C.; Jung, P.; Zhang, X.H.; et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22, 571–584.
  34. Colak, S.; Ten Dijke, P. Targeting TGF-beta Signaling in Cancer. Trends Cancer 2017, 3, 56–71.
  35. Calon, A.; Lonardo, E.; Berenguer-Llergo, A.; Espinet, E.; Hernando-Momblona, X.; Iglesias, M.; Sevillano, M.; Palomo-Ponce, S.; Tauriello, D.V.; Byrom, D.; et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 2015, 47, 320–329.
  36. Itatani, Y.; Kawada, K.; Sakai, Y. Transforming Growth Factor-beta Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. Int. J. Mol. Sci. 2019, 20, 5822.
  37. Koliaraki, V.; Pallangyo, C.K.; Greten, F.R.; Kollias, G. Mesenchymal Cells in Colon Cancer. Gastroenterology 2017, 152, 964–979.
  38. Tauriello, D.V.F.; Palomo-Ponce, S.; Stork, D.; Berenguer-Llergo, A.; Badia-Ramentol, J.; Iglesias, M.; Sevillano, M.; Ibiza, S.; Canellas, A.; Hernando-Momblona, X.; et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018, 554, 538–543.
  39. Bauer, J.; Emon, M.A.B.; Staudacher, J.J.; Thomas, A.L.; Zessner-Spitzenberg, J.; Mancinelli, G.; Krett, N.; Saif, M.T.; Jung, B. Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic activin A signaling. Sci. Rep. 2020, 10, 50.
  40. Wang, D.; Wang, X.; Song, Y.; Si, M.; Sun, Y.; Liu, X.; Cui, S.; Qu, X.; Yu, X. Exosomal miR-146a-5p and miR-155-5p promote CXCL12/CXCR7-induced metastasis of colorectal cancer by crosstalk with cancer-associated fibroblasts. Cell Death Dis. 2022, 13, 380.
  41. Liu, J.; Huang, Z.; Chen, H.-N.; Qin, S.; Chen, Y.; Jiang, J.; Zhang, Z.; Luo, M.; Ye, Q.; Xie, N.; et al. ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-β axis in colorectal cancer. Oncogene 2021, 40, 3394–3407.
  42. Peng, C.; Zou, X.; Xia, W.; Gao, H.; Li, Z.; Liu, N.; Xu, Z.; Gao, C.; He, Z.; Niu, W.; et al. Integrin αvβ6 plays a bi-directional regulation role between colon cancer cells and cancer-associated fibroblasts. Biosci. Rep. 2018, 38, BSR20180243.
  43. Wawro, M.E.; Sobierajska, K.; Ciszewski, W.M.; Niewiarowska, J. Nonsteroidal Anti-Inflammatory Drugs Prevent Vincristine-Dependent Cancer-Associated Fibroblasts Formation. Int. J. Mol. Sci. 2019, 20, 1941.
  44. Paauwe, M.; Schoonderwoerd, M.J.A.; Helderman, R.F.C.P.; Harryvan, T.J.; Groenewoud, A.; van Pelt, G.W.; Bor, R.; Hemmer, D.M.; Versteeg, H.H.; Snaar-Jagalska, B.E.; et al. Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis. Clin. Cancer Res. 2018, 24, 6331–6344.
  45. Ouahoud, S.; Voorneveld, P.W.; van der Burg, L.R.A.; de Jonge-Muller, E.S.M.; Schoonderwoerd, M.J.A.; Paauwe, M.; de Vos, T.; de Wit, S.; van Pelt, G.W.; Mesker, W.E.; et al. Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer. Oncogene 2020, 39, 2453–2466.
  46. Mizerska-Kowalska, M.; Sawa-Wejksza, K.; Slawinska-Brych, A.; Kandefer-Szerszen, M.; Zdzisinska, B. Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-beta1 synthesis in indirect co-cultures with normal colon fibroblasts. Clin. Transl. Oncol. 2021, 23, 1405–1414.
  47. Gonzalez-Zubeldia, I.; Dotor, J.; Redrado, M.; Bleau, A.-M.; Manrique, I.; de Aberasturi, A.L.; Villalba, M.; Calvo, A. Co-migration of colon cancer cells and CAFs induced by TGFβ1 enhances liver metastasis. Cell Tissue Res. 2015, 359, 829–839.
  48. Zhang, Y.; Wang, S.; Lai, Q.; Fang, Y.; Wu, C.; Liu, Y.; Li, Q.; Wang, X.; Gu, C.; Chen, J.; et al. Cancer-associated fibroblasts-derived exosomal miR-17-5p promotes colorectal cancer aggressive phenotype by initiating a RUNX3/MYC/TGF-β1 positive feedback loop. Cancer Lett. 2020, 491, 22–35.
  49. Guillén Díaz-Maroto, N.; Sanz-Pamplona, R.; Berdiel-Acer, M.; Cimas, F.J.; García, E.; Gonçalves-Ribeiro, S.; Albert, N.; Garcia-Vicién, G.; Capella, G.; Moreno, V.; et al. Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer. Clin. Cancer Res. 2019, 25, 4466–4479.
  50. Tan, H.-X.; Gong, W.-Z.; Zhou, K.; Xiao, Z.-G.; Hou, F.-T.; Huang, T.; Zhang, L.; Dong, H.-Y.; Zhang, W.-L.; Liu, Y.; et al. CXCR4/TGF-β1 mediated hepatic stellate cells differentiation into carcinoma-associated fibroblasts and promoted liver metastasis of colon cancer. Cancer Biol. Ther. 2020, 21, 258–268.
  51. Tan, H.-X.; Xiao, Z.-G.; Huang, T.; Fang, Z.-X.; Liu, Y.; Huang, Z.-C. CXCR4/TGF-β1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development. Cancer Biol. Ther. 2020, 21, 248–257.
  52. McAndrews, K.M.; Vazquez-Arreguin, K.; Kwak, C.; Sugimoto, H.; Zheng, X.; Li, B.; Kirtley, M.L.; LeBleu, V.S.; Kalluri, R. alphaSMA(+) fibroblasts suppress Lgr5(+) cancer stem cells and restrain colorectal cancer progression. Oncogene 2021, 40, 4440–4452.
  53. Kobayashi, H.; Gieniec, K.A.; Wright, J.A.; Wang, T.; Asai, N.; Mizutani, Y.; Lida, T.; Ando, R.; Suzuki, N.; Lannagan, T.R.M.; et al. The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. Gastroenterology 2021, 160, 1224–1239.e30.
  54. Wang, Y.; Xu, X.; Marshall, J.E.; Gong, M.; Zhao, Y.; Dua, K.; Hansbro, P.M.; Xu, J.; Liu, G. Loss of Hyaluronan and Proteoglycan Link Protein-1 Induces Tumorigenesis in Colorectal Cancer. Front. Oncol. 2021, 11, 754240.
  55. Wang, H.; Tian, T.; Zhang, J. Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. Int. J. Mol. Sci. 2021, 22, 8470.
  56. Cassetta, L.; Pollard, J.W. Targeting macrophages: Therapeutic approaches in cancer. Nat Rev. Drug Discov. 2018, 17, 887–904.
  57. Liu, C.; Zhang, W.; Wang, J.; Si, T.; Xing, W. Tumor-associated macrophage-derived transforming growth factor-β promotes colorectal cancer progression through HIF1-TRIB3 signaling. Cancer Sci. 2021, 112, 4198–4207.
  58. Ding, Y.; Hao, K.; Li, Z.; Ma, R.; Zhou, Y.; Zhou, Z.; Wei, M.; Liao, Y.; Dai, Y.; Yang, Y.; et al. c-Fos separation from Lamin A/C by GDF15 promotes colon cancer invasion and metastasis in inflammatory microenvironment. J. Cell. Physiol. 2020, 235, 4407–4421.
  59. Shimizu, Y.; Amano, H.; Ito, Y.; Betto, T.; Yamane, S.; Inoue, T.; Nishizawa, N.; Matsui, Y.; Kamata, M.; Nakamura, M.; et al. Angiotensin II subtype 1a receptor signaling in resident hepatic macrophages induces liver metastasis formation. Cancer Sci. 2017, 108, 1757–1768.
  60. Zhao, P.; Wang, B.; Zhang, Z.; Zhang, W.; Liu, Y. Response gene to complement 32 expression in macrophages augments paracrine stimulation-mediated colon cancer progression. Cell Death Dis. 2019, 10, 776.
  61. Chen, T.W.; Hung, W.Z.; Chiang, S.F.; Chen, W.T.; Ke, T.W.; Liang, J.A.; Huang, C.Y.; Yang, P.C.; Huang, K.C.; Chao, K.S.C. Dual inhibition of TGFbeta signaling and CSF1 CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Lett. 2022, 543, 215795.
  62. Shapouri-Moghaddam, A.; Mohammadian, S.; Vazini, H.; Taghadosi, M.; Esmaeili, S.-A.; Mardani, F.; Seifi, B.; Mohammadi, A.; Afshari, J.T.; Sahebkar, A. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol. 2018, 233, 6425–6440.
  63. Ma, X.; Gao, Y.; Chen, Y.; Liu, J.; Yang, C.; Bao, C.; Wang, Y.; Feng, Y.; Song, X.; Qiao, S. M2-Type Macrophages Induce Tregs Generation by Activating the TGF-beta/Smad Signalling Pathway to Promote Colorectal Cancer Development. OncoTargets Ther. 2021, 14, 5391–5402.
  64. Cai, J.; Xia, L.; Li, J.; Ni, S.; Song, H.; Wu, X. Tumor-Associated Macrophages Derived TGF-β–Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway. Cancer Res. Treat. 2019, 51, 252–266.
  65. Zhang, X.-L.; Hu, L.-P.; Yang, Q.; Qin, W.-T.; Wang, X.; Xu, C.-J.; Tian, G.-A.; Yang, X.-M.; Yao, L.-L.; Zhu, L.; et al. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer. Oncogene 2021, 40, 3959–3973.
  66. Li, Z.; Xu, W.; Yang, J.; Wang, J.; Wang, J.; Zhu, G.; Li, D.; Ding, J.; Sun, T. A Tumor Microenvironments-Adapted Polypeptide Hydrogel/Nanogel Composite Boosts Antitumor Molecularly Targeted Inhibition and Immunoactivation. Adv. Mater. 2022, 34, e2200449.
  67. Rao, H.-L.; Chen, J.-W.; Li, M.; Xiao, Y.-B.; Fu, J.; Zeng, Y.-X.; Cai, M.-Y.; Xie, D. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS ONE 2012, 7, e30806.
  68. Qin, F.; Liu, X.; Chen, J.; Huang, S.; Wei, W.; Zou, Y.; Liu, X.; Deng, K.; Mo, S.; Chen, J.; et al. Anti-TGF-β attenuates tumor growth via polarization of tumor associated neutrophils towards an anti-tumor phenotype in colorectal cancer. J. Cancer 2020, 11, 2580–2592.
  69. Jackstadt, R.; van Hooff, S.R.; Leach, J.D.; Cortes-Lavaud, X.; Lohuis, J.O.; Ridgway, R.A.; Wouters, V.M.; Roper, J.; Kendall, T.J.; Roxburgh, C.S.; et al. Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. Cancer Cell 2019, 36, 319–336.e7.
  70. Itatani, Y.; Kawada, K.; Fujishita, T.; Kakizaki, F.; Hirai, H.; Matsumoto, T.; Iwamoto, M.; Inamoto, S.; Hatano, E.; Hasegawa, S.; et al. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology 2013, 145, 1064–1075.e11.
  71. Xing, W.; Xiao, Y.; Lu, X.; Zhu, H.; He, X.; Huang, W.; Lopez, E.S.; Wong, J.; Ju, H.; Tian, L.; et al. GFI1 downregulation promotes inflammation-linked metastasis of colorectal cancer. Cell Death Differ. 2017, 24, 929–943.
  72. Wang, J.Q.; Tang, Y.; Li, Q.S.; Xiao, M.; Li, M.; Sheng, Y.T.; Yang, Y.; Wang, Y.L. PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NFkappaB in tumour metastases of colon carcinoma. Oncol. Rep. 2019, 41, 2657–2666.
  73. Miteva, L.D.; Stanilov, N.S.; Cirovski Gcapital Em, C.; Stanilova, S.A. Upregulation of Treg-Related Genes in Addition with IL6 Showed the Significant Role for the Distant Metastasis in Colorectal Cancer. Cancer Microenviron. 2017, 10, 69–76.
  74. Batlle, E.; Clevers, H. Cancer stem cells revisited. Nat. Med. 2017, 23, 1124–1134.
  75. Zeuner, A.; Todaro, M.; Stassi, G.; De Maria, R. Colorectal cancer stem cells: From the crypt to the clinic. Cell Stem Cell 2014, 15, 692–705.
  76. Oh, I.R.; Raymundo, B.; Kim, M.; Kim, C.W. Mesenchymal stem cells co-cultured with colorectal cancer cells showed increased invasive and proliferative abilities due to its altered p53/TGF-beta1 levels. Biosci. Biotechnol. Biochem. 2020, 84, 256–267.
  77. Niu, B.; Liu, J.; Lv, B.; Lin, J.; Li, X.; Wu, C.; Jiang, X.; Zeng, Z.; Zhang, X.K.; Zhou, H. Interplay between transforming growth factor-beta and Nur77 in dual regulations of inhibitor of differentiation 1 for colonic tumorigenesis. Nat. Commun. 2021, 12, 2809.
  78. Wang, J.; Zhang, B.; Wu, H.; Cai, J.; Sui, X.; Wang, Y.; Li, H.; Qiu, Y.; Wang, T.; Chen, Z.; et al. CD51 correlates with the TGF-beta pathway and is a functional marker for colorectal cancer stem cells. Oncogene 2017, 36, 1351–1363.
  79. Fujishita, T.; Kojima, Y.; Kajino-Sakamoto, R.; Mishiro-Sato, E.; Shimizu, Y.; Hosoda, W.; Yamaguchi, R.; Taketo, M.M.; Aoki, M. The cAMP/PKA/CREB and TGF-β/SMAD4 pathways regulate stemness and metastatic potential in colorectal cancer cells. Cancer Res. 2022, 82, 4179–4190.
  80. Krstic, J.; Santibanez, J.F. Transforming growth factor-beta and matrix metalloproteinases: Functional interactions in tumor stroma-infiltrating myeloid cells. Sci. World J. 2014, 2014, 521754.
  81. Lee, H.; Kong, J.S.; Lee, S.S.; Kim, A. Radiation-Induced Overexpression of TGFbeta and PODXL Contributes to Colorectal Cancer Cell Radioresistance through Enhanced Motility. Cells 2021, 10, 2087.
  82. Jia, H.; Yang, Y.; Li, M.; Chu, Y.; Song, H.; Zhang, J.; Zhang, D.; Zhang, Q.; Xu, Y.; Wang, J.; et al. Snail enhances arginine synthesis by inhibiting ubiquitination-mediated degradation of ASS1. EMBO Rep. 2021, 22, e51780.
  83. Zajac, O.; Raingeaud, J.; Libanje, F.; Lefebvre, C.; Sabino, D.; Martins, I.; Roy, P.; Benatar, C.; Canet-Jourdan, C.; Azorin, P.; et al. Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas. Nat. Cell Biol. 2018, 20, 296–306.
  84. Kim, M.S.; Suh, K.W.; Hong, S.; Jin, W. TrkC promotes colorectal cancer growth and metastasis. Oncotarget 2017, 8, 41319–41333.
  85. Song, J.; Chen, W.; Cui, X.; Huang, Z.; Wen, D.; Yang, Y.; Yu, W.; Cui, L.; Liu, C.Y. CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFbeta signaling in colorectal cancer. Theranostics 2020, 10, 2327–2341.
  86. Haidar, M.; Metheni, M.; Batteux, F.; Langsley, G. TGF-beta2, catalase activity, H2O2 output and metastatic potential of diverse types of tumour. Free Radic. Biol. Med. 2019, 134, 282–287.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , ,
View Times: 404
Entry Collection: Gastrointestinal Disease
Revisions: 3 times (View History)
Update Date: 01 Dec 2022
1000/1000